Here’s what you need to know.
1. The trial will be used to support a premarket approval application which will allow the GelrinC to be marketed in the U.S.
2. Focal defects of in the cartilage of the knee are caused by a result of trauma and can be painful to patients. They often require intervention.
The GelrinC is minimally invasive. It is administered as a liquid, and then is converted into a solid after being exposed to ultraviolet light. The implant degrades within six months to a year, and is replaced with functional and durable cartilage.
3. Rush University Medical Center’s Assistant Chairman and Professor in the department of Orthopedics Brian Cole, MD, said, “GelrinC is a potential game changer in the cartilage repair space, and can be an attractive and viable option for patients.”
More orthopedic device news:
6 key observations on robotic technology for spine surgery
Global spine surgical robots market to spike to $2.77B by 2022: 5 observations
AMA includes 1st endoscopic spine surgery code in 2017 codebook: 6 things to know
